Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1.

Oncolytic viral (OV) therapy is a promising therapeutic modality for brain tumors. Vasculostatin (Vstat120) is the cleaved and secreted extracellular fragment of brain-specific angiogenesis inhibitor 1 (BAI1), a brain-specific receptor. To date, the therapeutic efficacy of Vstat120 delivery into established tumors has not been investigated. Here we tested the therapeutic efficacy of combining Vstat120 gene delivery in conjunction with OV therapy. We constructed RAMBO (Rapid Antiangiogenesis Mediated By Oncolytic virus), which expresses Vstat120 under the control of the herpes simplex virus (HSV) IE4/5 promoter. Secreted Vstat120 was detected as soon as 4 hours postinfection in vitro and was retained for up to 13 days after OV therapy in subcutaneous tumors. RAMBO-produced Vstat120 efficiently inhibited endothelial cell migration and tube formation in vitro (P = 0.0005 and P = 0.0184, respectively) and inhibited angiogenesis (P = 0.007) in vivo. There was a significant suppression of intracranial and subcutaneous glioma growth in mice treated with RAMBO compared to the control virus, HSVQ (P = 0.0021 and P < 0.05, respectively). Statistically significant reduction in tumor vascular volume fraction (VVF) and microvessel density (MVD) was observed in tumors treated with RAMBO. This is the first study to report the antitumor effects of Vstat120 delivery into established tumors and supports the further development of RAMBO as a possible cancer therapy.

• Publication year

  2010

• Venue

  Molecular Therapy

• Publication date

  2010-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/mt.2009.232PMID 19844198PMCID PMC2818668
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.

  2009cited by this paper
• Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

  2009cited by this paper
• Advances in oncolytic virus therapy for glioma.

  2009cited by this paper
• Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.

  2009cited by this paper
• Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus dl922-947

  2008cited by this paper
• Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.

  2008cited by this paper
• Thrombospondins: from structure to therapeutics

  2008cited by this paper
• CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma.

  2008cited by this paper
• Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

  2008cited by this paper
• Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.

  2007cited by this paper
• Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma.

  2007cited by this paper
• Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

  2007cited by this paper
• Gene expression profiling of metastatic brain cancer.

  2007cited by this paper
• Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.

  2007cited by this paper
• The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration.

  2007cited by this paper
• Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.

  2007cited by this paper
• Tomographic fluorescence imaging of tumor vascular volume in mice.

  2007cited by this paper
• BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module

  2007cited by this paper
• Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models

  2006cited by this paper
• Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

  2006cited by this paper
• Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas

  2006cited by this paper
• Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

  2006cited by this paper
• Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors

  2006cited by this paper
• Paradoxical roles of the immune system during cancer development

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Early events in HSV keratitis--setting the stage for a blinding disease.

  2005cited by this paper
• An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

  2005cited by this paper
• Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes.

  2005cited by this paper
• Vasculostatin, a proteolytic fragment of Brain Angiogenesis Inhibitor 1, is an antiangiogenic and antitumorigenic factor

  2005cited by this paper
• Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression

  2005cited by this paper
• Extracellular fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking alphavbeta5 integrin.

  2004cited by this paper
• Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance.

  2004cited by this paper
• Extracellular fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking αvβ5 integrin

  2004cited by this paper
• Oncolysis by viral replication and inhibition of angiogenesis by a replication‐conditional herpes simplex virus that expresses mouse endostatin

  2004cited by this paper
• Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.

  2004cited by this paper
• A critical role of placental growth factor in the induction of inflammation and edema formation.

  2003cited by this paper
• Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression.

  2003cited by this paper
• Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas

  2003cited by this paper
• Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus.

  2002cited by this paper
• Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis

  2001cited by this paper
• Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer.

  2001cited by this paper
• Thrombospondins and tumor angiogenesis.

  2001cited by this paper
• Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

  2000cited by this paper
• Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.

  2000cited by this paper
• Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1).

  2000cited by this paper
• Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in Mice

  2000cited by this paper
• Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer.

  1998cited by this paper
• CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth.

  1998cited by this paper
• A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis

  1997cited by this paper
• Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism.

  1994cited by this paper
• p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

  1989cited by this paper

• Practical and translational therapeutic elements for GBM therapy.

  2026cites this paper
• Adhesion G protein-coupled receptors

  2026cites this paper
• Functional diversity of BAI1 (ADGRB1): From angiostasis to synaptic remodeling and disease therapeutics

  2026cites this paper
• Adhesion Class GPCRs in GtoPdb v.2025.3

  2025cites this paper
• A Review of Novel Cancer Therapeutics and Current Research Trends

  2025cites this paper
• The N terminus-only function of adhesion GPCRs: emerging concepts.

  2025cites this paper
• Oncolytic HSV and cancer drug interactions: Current clinical status and future directions

  2025cites this paper
• Glioblastoma Therapy: Past, Present and Future

  2024cites this paper
• Development and assessment of cutting-edge biotechnologies

  2024cites this paper
• Molecular insights and promise of oncolytic virus based immunotherapy.

  2024cites this paper
• Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy

  2024cites this paper
• Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments

  2024cites this paper
• 4-1BBL-Armed Oncolytic Herpes Simplex Virus Exerts Antitumor Effects in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Adhesion Class GPCRs in GtoPdb v.2023.1 Adhesion Class GPCRs in GtoPdb v.2023.1

  2023cites this paper
• Implications of immune cells in oncolytic herpes simplex virotherapy for glioma

  2022cites this paper
• The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics

  2022cites this paper
• Molecular Mechanisms and Clinical Challenges of Glioma Invasion

  2022cites this paper
• Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy

  2022cites this paper
• Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo

  2021cites this paper
• The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment

  2021cites this paper
• Oncolytic HSV: Underpinnings of Tumor Susceptibility

  2021cites this paper
• OV_A_268426 1..27

  2021cites this paper
• Adhesion Class GPCRs in GtoPdb v.2021.3

  2021cites this paper
• β-Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer

  2021cites this paper
• The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment

  2021cites this paper
• Advances in Synthetic Biology and Biosafety Governance

  2021cites this paper
• Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy

  2021cites this paper
• Enhancing Antitumor Efficacy of Heavily Vascularized Tumors by RAMBO Virus through Decreased Tumor Endothelial Cell Activation

  2020cites this paper
• Oncolytic Virotherapy in Glioma Tumors

  2020influential citation
• Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity

  2020cites this paper
• New viral vectors for infectious diseases and cancer.

  2020cites this paper
• BAI1 Acts as a Tumor Suppressor in Triple-Negative Breast Cancer via Modulating p73 Transactivation

  2020cites this paper
• Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

  2019cites this paper
• Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways

  2019influential citation
• Current Challenges and Applications of Oncolytic Viruses in Overcoming the Development of Resistance to Therapies in Cancer

  2019cites this paper
• Oncolytic Herpes Simplex Virus Immunotherapy for Brain Tumors: Current Pitfalls and Emerging Strategies to Overcome Therapeutic Resistance

  2019influential citation
• Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth

  2019cites this paper
• Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.

  2019cites this paper
• Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application

  2019cites this paper
• Adhesion Class GPCRs (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Evaluation of Oncolytic and Immunomodulatory Potential of the HSV-1 Live-Attenuated Vaccine Strain VC2 in an Immunocompetent Murine Melanoma Model

  2018cites this paper
• Suppression of HMGB1 Released in the Glioblastoma Tumor Microenvironment Reduces Tumoral Edema

  2018cites this paper
• PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance

  2018cites this paper
• Herpes Simplex Virus Type 1 for Use in Cancer Gene Therapy: Looking Backward to Move Forward

  2018cites this paper
• Oncolytic Herpes Simplex Viruses as a Paradigm for the Treatment of Cancer

  2018cites this paper
• Herpes Simplex Virus Type 1 for Use in Cancer Gene Therapy : Looking Backward to Move

  2017cites this paper
• Regulatory roles of brain-specific angiogenesis inhibitor 1(BAI1) protein in inflammation, tumorigenesis and phagocytosis: A brief review.

  2017cites this paper
• Adhesion molecules and the extracellular matrix as drug targets for glioma

  2016cites this paper
• A Walk on the Fine Line Between Reward and Risk: AAV-IFNβ Gene Therapy for Glioblastoma: A Dissertation

  2016cites this paper
• BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy

  2016cites this paper
• Oncotarget Strategies For Herpes Simplex Virus-1.

  2016cites this paper
• PHARMREV009647 338..367

  2015cites this paper
• Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft

  2015cites this paper
• International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein–Coupled Receptors

  2015cites this paper
• Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children

  2015cites this paper
• ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma

  2015cites this paper
• Oncolytic virotherapy using herpes simplex virus: how far have we come?

  2015cites this paper
• Sui generis: gene therapy and delivery systems for the treatment of glioblastoma.

  2015cites this paper
• Designing herpes viruses as oncolytics

  2015cites this paper
• Targeting tumor vasculature through oncolytic virotherapy: recent advances

  2015cites this paper
• Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer

  2014cites this paper
• Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10

  2014cites this paper
• Herpes Simplex Virus

  2014cites this paper
• Changes in BAI1 and Nestin Expression Are Prognostic Indicators for Survival and Metastases in Breast Cancer and Provide Opportunities for Dual Targeted Therapies

  2014cites this paper
• Enhanced Antitumor Efficacy of an Oncolytic Herpes Simplex Virus Expressing an Endostatin–Angiostatin Fusion Gene in Human Glioblastoma Stem Cell Xenografts

  2014cites this paper
• A Novel Oncolytic Herpes Simplex Virus Type 2 Has Potent Anti-Tumor Activity

  2014cites this paper
• Modification of HSV-1 to an oncolytic virus.

  2014cites this paper
• Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy

  2014cites this paper
• Cancer Therapy : Preclinical DoxorubicinSynergizeswith 34 . 5 ENVE toEnhanceAntitumor Ef fi cacy against Metastatic Ovarian Cancer

  2014cites this paper
• Targeting Tumour Vasculature with Oncolytic Viruses

  2014cites this paper
• Choindroitinase ABC I-Mediated Enhancement of Oncolytic Virus Spread and Anti Tumor Efficacy: A Mathematical Model

  2014cites this paper
• Role of microRNAs in mechanisms of glioblastoma resistance to radio- and chemotherapy

  2013cites this paper
• HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy

  2013cites this paper
• Current status of gene therapy for brain tumors.

  2013cites this paper
• The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus

  2013cites this paper
• Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.

  2013cites this paper
• Strategies in Gene Therapy for Glioblastoma

  2013cites this paper
• Update on oncolytic viral therapy – targeting angiogenesis

  2013cites this paper
• The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy

  2013cites this paper
• Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy

  2013cites this paper
• An armed oncolytic herpes simplex virus expressing thrombospondin‐1 has an enhanced in vivo antitumor effect against human gastric cancer

  2013cites this paper
• VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

  2013cites this paper
• Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model

  2013cites this paper
• Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses.

  2013cites this paper
• Oncolytic Virus Therapy in Combination with Chemotherapy for Ovarian Cancer

  2013cites this paper
• Copper Chelation Enhances Antitumor Efficacy and Systemic Delivery of Oncolytic HSV

  2012cites this paper
• Extracellular Vesicles and Their Convergence with Viral Pathways

  2012cites this paper
• Novel Therapies in Glioblastoma

  2012cites this paper
• Stem Cells and Cancer Stem Cells, Volume 1

  2012cites this paper
• The Effect of the Tumor Microenvironment on Oncolytic Virus Therapy for Glioblastoma

  2012influential citation
• Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy

  2012cites this paper
• CopperChelationEnhancesAntitumorEfficacyandSystemic Delivery of Oncolytic HSV

  2012cites this paper
• Glioblastoma-Derived Cancer Stem Cells: Treatment with Oncolytic Viruses

  2012cites this paper
• Novel therapies for high-grade gliomas: A vision for future

  2012cites this paper
• Gene and Viral Therapy for Glioblastoma: A Review of Clinical Trials and Future Directions

  2012cites this paper
• Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

  2012cites this paper
• Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

  2012cites this paper
• Cancer Therapy: Preclinical CopperChelationEnhancesAntitumorEfficacyandSystemic Delivery of Oncolytic HSV

  2012cites this paper
• Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential.

  2012cites this paper
• A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1

  2012cites this paper